Despite recent advances in hepatitis C (HCV) treatment, specifically the addition of direct
acting antivirals (DAAs), pegylated interferon-alpha remains the backbone of HCV therapy.
Therefore, the impact of DAAs on the management of co-morbid psychiatric illness and
neuropsychiatric sequalae remains an ongoing concern during HCV therapy. This paper
provides a review of the neuropsychiatric adverse effects of DAAs and drug-drug interactions
(DDIs) between DAAs and psychiatric medications.
Adverse drug reaction and pharmacovigilance.Shrawan Gehlot
Any unwanted or undesirable effect or noxious change due to a drug which occurs at doses used in human for prophylaxis, diagnosis or therapy, are known as Adverse Drug Reaction.
Pharmacovigilance is concerned with the detection, assessment and prevention of adverse reaction of drug.
This document defines adverse drug reactions and types of adverse reactions. It provides:
1) A definition of adverse drug reaction from WHO as any unwanted effects that occur from normal drug doses used for treatment or prevention of diseases.
2) Classifications of adverse reactions including type A reactions which are augmented or increased pharmacological effects, type B bizarre reactions which cannot be predicted, and type C chemical reactions related to a drug's structure.
3) Descriptions of other types such as delayed reactions occurring after long term use and exit reactions occurring on drug withdrawal. Examples are provided for each type of adverse drug reaction.
This document discusses drug idiosyncrasy and adverse drug reactions. It defines drug idiosyncrasy as an abnormal genetic response to a drug in some individuals. Idiosyncratic reactions are non-dose related and unpredictable. The document categorizes and classifies different types of adverse drug reactions and discusses methods of detection, including pre-marketing clinical trials and post-marketing surveillance. It emphasizes the importance of reporting suspected adverse drug reactions to help prevent future harm.
This document discusses adverse drug reactions (ADRs). It defines an ADR as an unwanted or harmful reaction that occurs after administration of a drug under normal conditions of use and is suspected to be related to the drug. ADRs can be caused by high drug doses, allergic reactions, or idiosyncratic reactions in some patients. Symptoms of ADRs may appear soon after the first dose or after chronic use, and can be obvious or subtle. Treatment of ADRs may involve modifying the dosage, discontinuing the drug, or switching to a different drug. Prevention requires familiarity with potential drug reactions and checking for interactions, especially in the elderly.
Adverse drug reaction , types ,Detection and Reporting,severity and seriousness(Hartwig'severity assessment), preventibility(Schumock and thornston) and predictability, causality assessment Naranjo"s algotithm, WHO UMC causality scale
This document defines key terms related to adverse drug reactions such as adverse events, adverse drug reactions, and medication errors. It describes the etiology and various classification systems for adverse drug reactions. The document outlines methods for detecting, reporting, and assessing the severity and seriousness of adverse drug reactions. It also covers predicting and preventing adverse drug reactions, and how to manage adverse drug reactions when they occur. The document emphasizes the importance of reporting all suspected adverse drug reactions to assist in ensuring drug safety.
Adverse drug reaction and pharmacovigilance.Shrawan Gehlot
Any unwanted or undesirable effect or noxious change due to a drug which occurs at doses used in human for prophylaxis, diagnosis or therapy, are known as Adverse Drug Reaction.
Pharmacovigilance is concerned with the detection, assessment and prevention of adverse reaction of drug.
This document defines adverse drug reactions and types of adverse reactions. It provides:
1) A definition of adverse drug reaction from WHO as any unwanted effects that occur from normal drug doses used for treatment or prevention of diseases.
2) Classifications of adverse reactions including type A reactions which are augmented or increased pharmacological effects, type B bizarre reactions which cannot be predicted, and type C chemical reactions related to a drug's structure.
3) Descriptions of other types such as delayed reactions occurring after long term use and exit reactions occurring on drug withdrawal. Examples are provided for each type of adverse drug reaction.
This document discusses drug idiosyncrasy and adverse drug reactions. It defines drug idiosyncrasy as an abnormal genetic response to a drug in some individuals. Idiosyncratic reactions are non-dose related and unpredictable. The document categorizes and classifies different types of adverse drug reactions and discusses methods of detection, including pre-marketing clinical trials and post-marketing surveillance. It emphasizes the importance of reporting suspected adverse drug reactions to help prevent future harm.
This document discusses adverse drug reactions (ADRs). It defines an ADR as an unwanted or harmful reaction that occurs after administration of a drug under normal conditions of use and is suspected to be related to the drug. ADRs can be caused by high drug doses, allergic reactions, or idiosyncratic reactions in some patients. Symptoms of ADRs may appear soon after the first dose or after chronic use, and can be obvious or subtle. Treatment of ADRs may involve modifying the dosage, discontinuing the drug, or switching to a different drug. Prevention requires familiarity with potential drug reactions and checking for interactions, especially in the elderly.
Adverse drug reaction , types ,Detection and Reporting,severity and seriousness(Hartwig'severity assessment), preventibility(Schumock and thornston) and predictability, causality assessment Naranjo"s algotithm, WHO UMC causality scale
This document defines key terms related to adverse drug reactions such as adverse events, adverse drug reactions, and medication errors. It describes the etiology and various classification systems for adverse drug reactions. The document outlines methods for detecting, reporting, and assessing the severity and seriousness of adverse drug reactions. It also covers predicting and preventing adverse drug reactions, and how to manage adverse drug reactions when they occur. The document emphasizes the importance of reporting all suspected adverse drug reactions to assist in ensuring drug safety.
Severity, seriousness, predictability and preventability assessmentDr. Ramesh Bhandari
This document discusses the assessment of severity and seriousness of adverse drug reactions (ADRs). It defines severity as the intensity of a medical event, categorizing ADRs as mild, moderate or severe based on management steps. It also describes several classification scales for ADR severity, including one by Karch and Lasagna and the Modified Hartwig's and Siegel Scale. The document defines seriousness classification according to regulatory criteria. It then discusses preventability and predictability of ADRs, describing scales by Schumock and Thornton for preventability and the distinction between Type A and Type B reactions in terms of predictability.
This document discusses adverse drug reactions (ADRs), defined as any undesirable or unintended consequence of drug administration. ADRs are classified as either predictable (type A) or unpredictable (type B) reactions. Predictable reactions include excessive pharmacological effects, secondary pharmacological effects, and rebound effects on drug discontinuation. Unpredictable reactions include allergic drug reactions, idiosyncrasy, and genetically determined toxicity. The document also covers ADR detection methods like patient interviews, ADR reporting approaches, and ADR management based on reaction severity and importance of continued treatment.
This document summarizes a study on polypharmacy among patients in South India. The study defined polypharmacy as using 2-4 drugs as minor polypharmacy and 5 or more drugs as major polypharmacy. It found that 59.82% of patients had major polypharmacy, occurring most in cardiovascular diseases. Polypharmacy was more prevalent in males and in ages 19-60 years. Hospital stays were longer for major polypharmacy. The study suggests simplifying treatment regimens by eliminating unnecessary drugs and dosages to reduce problems from polypharmacy.
Variations in psychopharmacology for elderly and childrenAhmed Elaghoury
1. The document discusses variations in psychopharmacology treatment for elderly and children populations.
2. Key factors to consider for elderly include medical history, potential drug interactions and screening for inappropriate prescriptions using criteria like Beers.
3. Variables in treating children include dosing based on weight and faster metabolism, minimum ages for certain drugs, and off-label prescribing being common.
This document discusses polypharmacy in psychiatry. It defines polypharmacy as using two or more medications to treat the same or different conditions. While historically frowned upon, polypharmacy is now seen as necessary in many cases. Studies show rates of polypharmacy vary widely, from 13-90%, and have increased over time. Polypharmacy is more common in certain populations like adult men, those with schizophrenia, and the geriatric population where over 90% use at least one medication per week. While polypharmacy can increase adverse effects and interactions, it may be justified when treating co-morbidities or when mono-therapy is insufficient. Education and following guidelines can help avoid irrational polypharmacy.
This document discusses adverse drug reactions (ADRs). It begins by defining key terms like adverse drug event, adverse drug reaction, and side effects. It then classifies ADRs into different types (A through E) based on their mechanism and provides examples. The document also discusses classifying ADRs by severity and the WHO's classification system involving temporal relationship and de-challenge/re-challenge. It introduces the Naranjo Algorithm for assessing causality of ADRs and the Schumock and Thornton scale for assessing preventability. In closing, it offers to answer any questions about ADRs.
detection methods of Adverse drug reactions, postal survey method, Reporting of Adverse drug reactions, Preventability assessment, predictability assessments
The document discusses the issues of polypharmacy and adverse drug reactions (ADRs) in elderly patients. It notes that polypharmacy is associated with reduced quality of life, increased healthcare costs, and preventable hospitalizations and deaths in seniors. The elderly have unique pharmacokinetics that increase their risk of ADRs. The document proposes a CARE approach to reduce polypharmacy and ADRs through caution, compliance, adjusting doses, regular review of medication regimens, and educating patients. It also recommends the use of a personal health record.
Overview of Medications to Treat Addiction in Primary CareCenter on Addiction
These materials provide information on prescribing details for FDA-approved medications used to treat addiction in primary care. Visit CASAColumbia.org for more details
Factors Affecting Non-Compliance among Psychiatric Patients in the Regional I...iosrphr_editor
The IOSR Journal of Pharmacy (IOSRPHR) is an open access online & offline peer reviewed international journal, which publishes innovative research papers, reviews, mini-reviews, short communications and notes dealing with Pharmaceutical Sciences( Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy & Phytochemistry, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest........more details on Aim & Scope).
03.03 management of patients on antiretroviral drugs changiDavid Ngogoyo
This document provides guidance on changing or stopping antiretroviral therapy (ART) in a rational manner. It describes the main reasons for altering a patient's ART regimen as drug toxicity, interactions, or treatment failure. It discusses how to diagnose and manage common adverse drug reactions and interactions. It emphasizes the importance of assessing adherence before changing a patient's failing regimen and consulting national treatment guidelines and experts when making decisions about second-line therapy.
Self-medication is a growing global concern that can contribute to antimicrobial resistance. While it provides benefits like convenience and cost savings, it also poses risks if not done properly, such as incorrect diagnosis, inappropriate treatment, and adverse drug reactions. Health professionals and pharmacists can help prevent these risks through education, guidance on proper use, and encouraging medical consultation when needed.
Patient compliance and assessment |Method of Assessment | Strategy to reduce ...Shaikh Abusufyan
For all III YouTube Live video lecture series of this topic click:
https://youtube.com/playlist?list=PLBVbJ9HCa1Bb8e-fFHIU5Srw3MNpy1U8B
For More Such Learning You Can Subscribe to
My YouTube Channel:
https://www.youtube.com/channel/UC5o-WkzmDJaF7udyAP2jtgw/featured?sub_confirmation=1
Facebook Page: https://www.facebook.com/asacademylearningforever
Website Blog: https://itasacademy.blogspot.com/
Patient medication adherence, Medication adherence, Causes of medication non-adherence, Problems linked with Medication Non-adherence, Factors affecting medication adherence, Patient related factors, Social and Economic factor, Disease related factor, Health care provider related factors, Therapy related factors, pharmacist role in the medication adherence, role of pharmacist in the medication adherence, monitoring of patient medication adherence, Direct method, Indirect method
This document discusses polypharmacy, which is defined as the administration of many drugs simultaneously or an excessive number of drugs. Polypharmacy is common in elderly patients with multiple chronic conditions. It can be appropriate if all drugs achieve therapeutic objectives and minimize adverse effects, but is often inappropriate if drugs are unnecessary or cause harm. Tools like Beers Criteria, STOPP, and START can help identify inappropriate polypharmacy and guide deprescribing. The document outlines factors contributing to polypharmacy and consequences like adverse drug reactions, providing strategies to assess medication benefit-harm and safely discontinue unnecessary drugs.
The presentation aims to give a basic understanding about the various drug reactions. It explains the mechanisms of ADR, Types, predisposing factors for ADR, and other common drug related adverse events
This document provides guidelines for pharmacological interventions in treating schizophrenia, including recommendations for initiating treatment with antipsychotic medication, how to use oral antipsychotic medication, recommendations for acute episodes, and promoting long-term recovery. It recommends choosing antipsychotics based on individual factors and monitoring for efficacy and side effects. It suggests considering depot/long-acting injectable antipsychotics or clozapine for non-responders and monitoring physical health in primary care.
Dr. Dalia Hamdy presented on aging and drugs. She discussed that the elderly population is growing significantly and they represent a major group of drug users. Providing safe and effective drug therapy for the elderly is challenging due to lack of clinical trials in this group and changes in physiology. Geriatric pharmacists can play an important role by assessing medication regimens for appropriateness, consulting with physicians on optimizing prescriptions, and providing counseling to improve medication adherence. Live applications of geriatric pharmacists were seen at Qatar University College of Pharmacy.
DBHDD launched the GEN Rx project in 2012 in 3 Georgia counties to reduce prescription drug misuse among 12-25 year olds. The goal was to address what the CDC classified as an epidemic of prescription drug abuse, as Rx drugs are abused more than other drugs combined by teens. The project aimed to educate about abuse vs misuse, risks of addiction, and short and long term effects through community involvement and points of contact provided.
This document discusses various challenges in using antiretroviral drugs to treat HIV, including factors related to the virus, the drugs, and the host. It covers existing drug classes like nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors. It also introduces new drug classes in development, such as entry inhibitors that target chemokine receptors or fusion. While antiretroviral treatment has improved life for many, ongoing research aims to address ongoing challenges like toxicity, resistance, and management of lifelong therapy.
Millions suffer from hepatitis C, which can lead to severe liver disease and death. New direct-acting antiviral (DAA) drugs show promise in eradicating the hepatitis C virus from the blood, but it is unclear if this leads to being virus-free and improved health outcomes. This review assesses the clinical effects of DAAs for hepatitis C.
DAAs directly target and inhibit viral proteins essential for hepatitis C replication, such as the NS3/4A protease, NS5A protein, and NS5B polymerase. Current hepatitis C treatments combine different DAA classes to stop viral copying and promise shorter treatment times and higher cure rates than previous options. Common side effects include flu-like symptoms
Severity, seriousness, predictability and preventability assessmentDr. Ramesh Bhandari
This document discusses the assessment of severity and seriousness of adverse drug reactions (ADRs). It defines severity as the intensity of a medical event, categorizing ADRs as mild, moderate or severe based on management steps. It also describes several classification scales for ADR severity, including one by Karch and Lasagna and the Modified Hartwig's and Siegel Scale. The document defines seriousness classification according to regulatory criteria. It then discusses preventability and predictability of ADRs, describing scales by Schumock and Thornton for preventability and the distinction between Type A and Type B reactions in terms of predictability.
This document discusses adverse drug reactions (ADRs), defined as any undesirable or unintended consequence of drug administration. ADRs are classified as either predictable (type A) or unpredictable (type B) reactions. Predictable reactions include excessive pharmacological effects, secondary pharmacological effects, and rebound effects on drug discontinuation. Unpredictable reactions include allergic drug reactions, idiosyncrasy, and genetically determined toxicity. The document also covers ADR detection methods like patient interviews, ADR reporting approaches, and ADR management based on reaction severity and importance of continued treatment.
This document summarizes a study on polypharmacy among patients in South India. The study defined polypharmacy as using 2-4 drugs as minor polypharmacy and 5 or more drugs as major polypharmacy. It found that 59.82% of patients had major polypharmacy, occurring most in cardiovascular diseases. Polypharmacy was more prevalent in males and in ages 19-60 years. Hospital stays were longer for major polypharmacy. The study suggests simplifying treatment regimens by eliminating unnecessary drugs and dosages to reduce problems from polypharmacy.
Variations in psychopharmacology for elderly and childrenAhmed Elaghoury
1. The document discusses variations in psychopharmacology treatment for elderly and children populations.
2. Key factors to consider for elderly include medical history, potential drug interactions and screening for inappropriate prescriptions using criteria like Beers.
3. Variables in treating children include dosing based on weight and faster metabolism, minimum ages for certain drugs, and off-label prescribing being common.
This document discusses polypharmacy in psychiatry. It defines polypharmacy as using two or more medications to treat the same or different conditions. While historically frowned upon, polypharmacy is now seen as necessary in many cases. Studies show rates of polypharmacy vary widely, from 13-90%, and have increased over time. Polypharmacy is more common in certain populations like adult men, those with schizophrenia, and the geriatric population where over 90% use at least one medication per week. While polypharmacy can increase adverse effects and interactions, it may be justified when treating co-morbidities or when mono-therapy is insufficient. Education and following guidelines can help avoid irrational polypharmacy.
This document discusses adverse drug reactions (ADRs). It begins by defining key terms like adverse drug event, adverse drug reaction, and side effects. It then classifies ADRs into different types (A through E) based on their mechanism and provides examples. The document also discusses classifying ADRs by severity and the WHO's classification system involving temporal relationship and de-challenge/re-challenge. It introduces the Naranjo Algorithm for assessing causality of ADRs and the Schumock and Thornton scale for assessing preventability. In closing, it offers to answer any questions about ADRs.
detection methods of Adverse drug reactions, postal survey method, Reporting of Adverse drug reactions, Preventability assessment, predictability assessments
The document discusses the issues of polypharmacy and adverse drug reactions (ADRs) in elderly patients. It notes that polypharmacy is associated with reduced quality of life, increased healthcare costs, and preventable hospitalizations and deaths in seniors. The elderly have unique pharmacokinetics that increase their risk of ADRs. The document proposes a CARE approach to reduce polypharmacy and ADRs through caution, compliance, adjusting doses, regular review of medication regimens, and educating patients. It also recommends the use of a personal health record.
Overview of Medications to Treat Addiction in Primary CareCenter on Addiction
These materials provide information on prescribing details for FDA-approved medications used to treat addiction in primary care. Visit CASAColumbia.org for more details
Factors Affecting Non-Compliance among Psychiatric Patients in the Regional I...iosrphr_editor
The IOSR Journal of Pharmacy (IOSRPHR) is an open access online & offline peer reviewed international journal, which publishes innovative research papers, reviews, mini-reviews, short communications and notes dealing with Pharmaceutical Sciences( Pharmaceutical Technology, Pharmaceutics, Biopharmaceutics, Pharmacokinetics, Pharmaceutical/Medicinal Chemistry, Computational Chemistry and Molecular Drug Design, Pharmacognosy & Phytochemistry, Pharmacology, Pharmaceutical Analysis, Pharmacy Practice, Clinical and Hospital Pharmacy, Cell Biology, Genomics and Proteomics, Pharmacogenomics, Bioinformatics and Biotechnology of Pharmaceutical Interest........more details on Aim & Scope).
03.03 management of patients on antiretroviral drugs changiDavid Ngogoyo
This document provides guidance on changing or stopping antiretroviral therapy (ART) in a rational manner. It describes the main reasons for altering a patient's ART regimen as drug toxicity, interactions, or treatment failure. It discusses how to diagnose and manage common adverse drug reactions and interactions. It emphasizes the importance of assessing adherence before changing a patient's failing regimen and consulting national treatment guidelines and experts when making decisions about second-line therapy.
Self-medication is a growing global concern that can contribute to antimicrobial resistance. While it provides benefits like convenience and cost savings, it also poses risks if not done properly, such as incorrect diagnosis, inappropriate treatment, and adverse drug reactions. Health professionals and pharmacists can help prevent these risks through education, guidance on proper use, and encouraging medical consultation when needed.
Patient compliance and assessment |Method of Assessment | Strategy to reduce ...Shaikh Abusufyan
For all III YouTube Live video lecture series of this topic click:
https://youtube.com/playlist?list=PLBVbJ9HCa1Bb8e-fFHIU5Srw3MNpy1U8B
For More Such Learning You Can Subscribe to
My YouTube Channel:
https://www.youtube.com/channel/UC5o-WkzmDJaF7udyAP2jtgw/featured?sub_confirmation=1
Facebook Page: https://www.facebook.com/asacademylearningforever
Website Blog: https://itasacademy.blogspot.com/
Patient medication adherence, Medication adherence, Causes of medication non-adherence, Problems linked with Medication Non-adherence, Factors affecting medication adherence, Patient related factors, Social and Economic factor, Disease related factor, Health care provider related factors, Therapy related factors, pharmacist role in the medication adherence, role of pharmacist in the medication adherence, monitoring of patient medication adherence, Direct method, Indirect method
This document discusses polypharmacy, which is defined as the administration of many drugs simultaneously or an excessive number of drugs. Polypharmacy is common in elderly patients with multiple chronic conditions. It can be appropriate if all drugs achieve therapeutic objectives and minimize adverse effects, but is often inappropriate if drugs are unnecessary or cause harm. Tools like Beers Criteria, STOPP, and START can help identify inappropriate polypharmacy and guide deprescribing. The document outlines factors contributing to polypharmacy and consequences like adverse drug reactions, providing strategies to assess medication benefit-harm and safely discontinue unnecessary drugs.
The presentation aims to give a basic understanding about the various drug reactions. It explains the mechanisms of ADR, Types, predisposing factors for ADR, and other common drug related adverse events
This document provides guidelines for pharmacological interventions in treating schizophrenia, including recommendations for initiating treatment with antipsychotic medication, how to use oral antipsychotic medication, recommendations for acute episodes, and promoting long-term recovery. It recommends choosing antipsychotics based on individual factors and monitoring for efficacy and side effects. It suggests considering depot/long-acting injectable antipsychotics or clozapine for non-responders and monitoring physical health in primary care.
Dr. Dalia Hamdy presented on aging and drugs. She discussed that the elderly population is growing significantly and they represent a major group of drug users. Providing safe and effective drug therapy for the elderly is challenging due to lack of clinical trials in this group and changes in physiology. Geriatric pharmacists can play an important role by assessing medication regimens for appropriateness, consulting with physicians on optimizing prescriptions, and providing counseling to improve medication adherence. Live applications of geriatric pharmacists were seen at Qatar University College of Pharmacy.
DBHDD launched the GEN Rx project in 2012 in 3 Georgia counties to reduce prescription drug misuse among 12-25 year olds. The goal was to address what the CDC classified as an epidemic of prescription drug abuse, as Rx drugs are abused more than other drugs combined by teens. The project aimed to educate about abuse vs misuse, risks of addiction, and short and long term effects through community involvement and points of contact provided.
This document discusses various challenges in using antiretroviral drugs to treat HIV, including factors related to the virus, the drugs, and the host. It covers existing drug classes like nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and protease inhibitors. It also introduces new drug classes in development, such as entry inhibitors that target chemokine receptors or fusion. While antiretroviral treatment has improved life for many, ongoing research aims to address ongoing challenges like toxicity, resistance, and management of lifelong therapy.
Millions suffer from hepatitis C, which can lead to severe liver disease and death. New direct-acting antiviral (DAA) drugs show promise in eradicating the hepatitis C virus from the blood, but it is unclear if this leads to being virus-free and improved health outcomes. This review assesses the clinical effects of DAAs for hepatitis C.
DAAs directly target and inhibit viral proteins essential for hepatitis C replication, such as the NS3/4A protease, NS5A protein, and NS5B polymerase. Current hepatitis C treatments combine different DAA classes to stop viral copying and promise shorter treatment times and higher cure rates than previous options. Common side effects include flu-like symptoms
An estimated 40-90% of patients acutely infected with HIV will experience flu-like symptoms, though acute HIV infection is often not recognized. Diagnosis involves testing for HIV antibodies and viral load, with differential diagnosis including infectious mononucleosis, influenza, and others. While treatment trials are limited, initiating antiretroviral therapy early in acute infection may theoretically decrease disease severity and progression by suppressing viral replication and mutation.
This document summarizes a clinical trial that evaluated the use of a homeopathic HIV nosode in treating HIV-infected individuals. 27 participants completed the 6-month trial where they were given either 30C or 50C potencies of the nosode. The trial found that 25.93% of participants showed a sustained reduction in viral load. CD4 counts increased by 20% in 18.52% at 12 weeks and 14.81% at 24 weeks. 52% of participants showed stability or improvement in CD4% at 24 weeks. 63% and 55% of participants showed overall health improvements at 12 and 24 weeks respectively. The trial concluded the nosode showed potential immunological benefits but larger studies are needed.
This document summarizes a cost-utility analysis comparing the standard therapy of ribavirin and pegylated interferon to newer sofosbuvir-based therapies for the treatment of hepatitis C genotype 1 and 3 patients in Portugal. For genotype 1 patients, the incremental cost-effectiveness ratio of sofosbuvir-based therapy was calculated to be 38,455€ per quality-adjusted life year gained compared to standard therapy. For genotype 3 patients, the standard therapy of ribavirin and pegylated interferon was found to be more effective and less costly than sofosbuvir-based therapy.
This document discusses women's and men's health issues related to infections. It presents a case study of a 68-year-old male admitted with community-acquired pneumonia and discusses appropriate treatment including continued empiric antibiotics. It also discusses a case of a 46-year-old female presenting with menopausal symptoms and recommends treatment options focusing on lifestyle modifications and medications to address her symptoms and elevated blood pressure.
Highly Active Antiretroviral Therapy (HAART) involves using a combination of at least three antiretroviral drugs to suppress the HIV virus and stop the progression of HIV disease. HAART decreases the viral load, improves immune function, and prevents opportunistic infections. The goals of HAART are to prolong life, improve quality of life, achieve maximal viral suppression, restore immune function, reduce HIV transmission, and rationally sequence drugs to limit toxicity while maintaining treatment options. Current guidelines recommend starting ART for all individuals regardless of CD4 count. Second line regimens are recommended when clinical or immunological failure occurs on first line therapy. Managing adverse events and comorbidities like hepatitis co-infection is also
This document provides information about Highly Active Antiretroviral Therapy (HAART) for treating HIV. It discusses the history and development of HAART, which involves using multiple antiretroviral drugs together to suppress the virus. Early combinations included two nucleoside reverse transcriptase inhibitors with a protease inhibitor. The goals of ART are to prolong life, improve quality of life, and reduce viral load and transmission risk while maintaining treatment options. Guidelines recommend starting ART for all individuals to reduce disease progression.
Highly Active Antiretroviral Therapy (HAART) involves using a combination of at least three antiretroviral drugs to suppress the HIV virus and stop the progression of HIV disease. HAART decreases the viral load, improves immune function, and prevents opportunistic infections. The goals of HAART are to prolong life, improve quality of life, maximize viral suppression, and reconstitute the immune system. Current guidelines recommend starting HAART for all HIV patients regardless of CD4 count. Proper counseling, adherence, monitoring, and management of side effects are important for the success of HAART.
This document discusses guidelines for monitoring HIV patients on antiretroviral treatment. It recommends monitoring baseline labs at treatment initiation, including CD4 count. Patients should be closely monitored in the first 6 months, including for treatment toxicity and failure. Labs and clinical assessments are recommended every 2-4 weeks initially, then every 6 months once stable. Toxicities may require switching antiretroviral drugs, like substituting TDF for kidney issues. The goal of monitoring is to ensure viral suppression through adherence and detecting problems promptly.
This systematic review and meta-analysis examined the association between depressive symptoms and adherence to antiretroviral therapy (ART) among people living with HIV. It analyzed data from 111 studies with 42,366 participants across low, middle, and high income countries. The analysis found that the rate of depressive symptoms among people living with HIV ranged from 12.8% to 78% across studies, while the rate of good ART adherence (≥80%) ranged from 20% to 98%. There was no significant difference in depressive symptom rates by country income, but good adherence was significantly higher in lower income countries (86%) than higher income countries (67.5%). The meta-analysis showed that people living with HIV with depressive symptoms had a
Pegylated interferon in cmbination with lamuvidine in hbv,reduced.final ,ghre...Shendy Sherif
1) The document compares the effectiveness of three treatment regimens for chronic hepatitis B in Egyptian patients: lamivudine alone, pegylated interferon alone, and a combination of the two.
2) Response rates ranged from 30.4% for lamivudine to 47.8% for pegylated interferon. The combination therapy had a 32% response rate.
3) Pegylated interferon was associated with fewer drug resistance mutations and better histological response compared to lamivudine alone, suggesting it may be the best front-line treatment option. However, response rates remained below desired levels, leaving room for improvement.
This document provides guidelines for antiretroviral therapy in Malaysia. It discusses factors to consider when initiating ART such as patient willingness and understanding of side effects. The goals of ART are to reduce HIV-related illness and death, improve quality of life, and suppress viral load. Treatment outcomes are measured by reduced infections, increased CD4 count, and decreased viral load. ART options have expanded and now include six classes of drugs. Fixed dose drug combinations can improve adherence by reducing pill burden.
This document provides guidelines for antiretroviral therapy in Malaysia. It outlines contributors and reviewers, then covers goals of ART including reducing morbidity and mortality while improving quality of life. It discusses factors to consider when initiating ART, available drug classes and fixed dose combinations, guidelines for assessing newly diagnosed and experienced patients, and important laboratory tests for evaluation and monitoring during treatment.
This document provides guidelines for the management of persons living with HIV, including recommendations for antiretroviral therapy (ART). It discusses the goals of ART which are to suppress HIV viral load, improve CD4 counts, delay drug resistance, and confer clinical benefits. Initiation of ART is recommended for all individuals regardless of CD4 count to reduce morbidity and mortality and prevent transmission. First-line regimens usually consist of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) plus an integrase strand transfer inhibitor (INSTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), or protease inhibitor (PI) with a booster. Adherence counseling and management of comorbid
The document discusses the issues surrounding individuals with dual diagnoses of both substance use disorders and infectious diseases like HIV/AIDS. It notes that dual disorders can increase HIV risk behaviors and impact access to treatment. Studies found high rates of mental illness and substance use among people living with HIV. The complex interactions between antiretroviral medications, drugs of abuse, and psychiatric medications can impact treatment outcomes for individuals with triple diagnoses. Integrated treatment approaches are needed to effectively manage these complex patients.
1) HIV-related pulmonary arterial hypertension (PAH) reduces survival rates by half compared to HIV patients without PAH. The prevalence of PAH among HIV-infected individuals in Africa ranges from 5-13% based on studies in several countries.
2) The pathophysiology of HIV-related PAH involves cytokines induced by HIV that cause endothelial and smooth muscle cell dysfunction, as well as HIV viral proteins such as Nef, Tat, and gp120 that cause vascular damage and remodeling.
3) While antiretroviral therapy has benefits for HIV-related PAH, more large prospective studies are needed to better understand outcomes, as current data on epidemiology and treatment come from small cross-sectional studies.
This document provides an overview of new oral medications for treating hepatitis C virus (HCV) infection, including NS3/4A protease inhibitors telaprevir and boceprevir. It discusses HCV genotypes and lifecycle, focusing on improved understanding of viral targets leading to drug discovery. NS3/4A protease inhibitors and NS5B polymerase inhibitors currently in clinical development are described, targeting polyprotein processing and HCV replication respectively. Nucleoside and non-nucleoside NS5B inhibitors as well as NS5A inhibitors and their mechanisms of action and clinical trial status are summarized.
Case # 29- The depressed man who thought he was out of options. .docxannandleola
Case # 29- The depressed man who thought he was out of options.
Depression has become a common mental disorder in our elderly population. This has caused a global concern for occur, geriatric patients, as depression often results in a significant burden for families as well as communities. Elderly people who suffer from depression may have an inferior baseline and record for medical assessments than those individuals without depression. Despite consistent evidence of the effectiveness of antidepressants for many with depression,
3
particularly those with more severe depression, remission rates are disappointingly low. An AHRQ-sponsored report found that only 46% of patients experienced remission from depression during 6 to 12 weeks of treatment with second-generation antidepressants. One major reason for this issue is non-adherence to medications and treatment plans. Studies have shown that patients' age, race and ethnicity are consistently associated with predictions of outcomes. (Rossom et al., 2016).
This case study involves a 69-year old man whose chief complaint is unremitting, chronic depression. After several years of medications and treatments, he feels hopeless for a recovery from his chronic depression. This assignments seeks to explore his family and social support systems, diagnostic testing, differential diagnosis and pharmacologic treatment options for this patient.
Questions for the client
How have you been sleeping lately?
How many times in the last week have you had feelings of hopelessness?
Are you having thoughts of harming yourself? Do you have a plan?
These questions are an important yet simple place to start when treating patients. Sleep disturbances plague much of the world's population and have shown to be a major indicator for mental health issues. Changes in sleep neurophysiology are often observed in depressive patients, and impaired sleep is, in many cases, the chief complaint of depression (Armitage, 2007). Depressed patients with sleep disturbance are likely to present more severe symptoms and difficulties in treatment. In addition, persistent insomnia is the most common residual symptom in depressed patients and is considered a vital predictor of depression relapse and may contribute to unpleasant clinical outcomes (Hinkelmann et al., 20120. Questions involving feelings of hopelessness and suicidal ideations with or without a plan relate to issues of patient safety. Across psychiatric disorders, hopelessness is associated with suicidal ideation and behavior. A meta-analysis of 166 longitudinal studies (sample size not reported) found that hopelessness was associated with an increased risk of ideation (Ribeiro, Huang, Fox, & Franklin, 2018).
Family and social support system
Family and social support systems are imperative for any patient in recovery. If the patient is agreeable to discussions with family members, then a discussion with his wife would be helpful. Researc.
Similar to Psychiatric treatment considerations with direct acting antivirals in hepatitis C (20)
Incidence of pneumonia and risk factors among patients with head and neck can...Enrique Moreno Gonzalez
This study investigated the incidence and patient- and treatment-related risk factors related to pneumonia acquired during radiotherapy (PNRT) in head and neck cancer (HNC) patients.
Gene expression analysis of a Helicobacter pyloriinfected and high-salt diet-...Enrique Moreno Gonzalez
Helicobacter pylori (H. pylori) infection and excessive salt intake are known as important risk factors for stomach cancer in humans. However, interactions of these two factors with gene expression profiles during gastric carcinogenesis remain unclear. In the present study, we investigated the global gene expression associated with stomach carcinogenesis and prognosis of human gastric cancer using a mouse model.
Acute myeloid leukemia (AML) is a hematopoietic malignancy with a dismal outcome in the majority of cases. A detailed understanding of the genetic alterations and gene expression changes that contribute to its pathogenesis is important to improve prognostication, disease monitoring, and therapy. In this context, leukemia-associated misexpression of microRNAs (miRNAs) has been studied, but no coherent picture has emerged yet, thus warranting further investigations.
Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable. However, preclinical experimental data explaining the interaction mechanism(s) are lacking. Our objective is to investigate the anticancer efficacy and mechanism of combined sorafenib and 5-FU therapy in vitro in HCC cell lines MHCC97H and SMMC-7721.
Differences in microRNA expression during tumor development in the transition...Enrique Moreno Gonzalez
The prostate is divided into three glandular zones, the peripheral zone (PZ), the transition zone (TZ), and the central zone. Most prostate tumors arise in the peripheral zone (70-75%) and in the transition zone (20-25%) while only 10% arise in the central zone. The aim of this study was to investigate if differences in miRNA expression could be a possible explanation for the difference in propensity of tumors in the zones of the prostate.
Multicentric and multifocal versus unifocal breast cancer: differences in the...Enrique Moreno Gonzalez
This study compared the expression of E-cadherin, β-catenin, and MUC1 in multicentric/multifocal breast cancers versus unifocal breast cancers of identical tumor size and grade. The study found significantly downregulated expression of E-cadherin in multicentric/multifocal cancers compared to unifocal cancers. In contrast, no significant differences were seen in β-catenin expression between the two groups. Within the unifocal group, E-cadherin and β-catenin expression were positively correlated, but this was not seen in the multicentric/multifocal group. The results suggest multicentric/multifocal and unifocal breast cancers differ in E-
The life in sight application study (LISA): design of a randomized controlled...Enrique Moreno Gonzalez
It is widely recognized that spiritual care plays an important role in physical and psychosocial well-being of cancer patients, but there is little evidence based research on the effects of spiritual care. We will conduct a randomized controlled trial on spiritual care using a brief structured interview scheme supported by an e-application. The aim is to examine whether an assisted reflection on life events and ultimate life goals can improve quality of life of cancer patients.
Clinical and experimental studies regarding the expression and diagnostic val...Enrique Moreno Gonzalez
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a multifunctional Ig-like cell adhesion molecule that has a wide range of biological functions. According to previous reports, serum CEACAM1 is dysregulated in different malignant tumours and associated with tumour progression. However, the serum CEACAM1 expression in nonsmall-cell lung carcinomas (NSCLC) is unclear. The different expression ratio of CEACAM1-S and CEACAM1-L isoform has seldom been investigated in NSCLC. This research is intended to study the serum CEACAM1 and the ratio of CEACAM1-S/L isoforms in NSCLC.
Assessment of preoperative exercise capacity in hepatocellular carcinoma pati...Enrique Moreno Gonzalez
Cardiopulmonary exercise testing measures oxygen uptake at increasing levels of work and predicts cardiopulmonary performance under conditions of stress, such as after abdominal surgery. Dynamic assessment of preoperative exercise capacity may be a useful predictor of postoperative prognosis. This study examined the relationship between preoperative exercise capacity and event-free survival in hepatocellular carcinoma (HCC) patients with chronic liver injury who underwent hepatectomy.
Overexpression of YAP 1 contributes to progressive features and poor prognosi...Enrique Moreno Gonzalez
Yes-associated protein 1 (YAP 1), the nuclear effector of the Hippo pathway, is a key regulator of organ size and a candidate human oncogene in multiple tumors. However, the expression dynamics of YAP 1 in urothelial carcinoma of the bladder (UCB) and its clinical/prognostic significance are unclear.
CXCR7 is induced by hypoxia and mediates glioma cell migration towards SDF-1a...Enrique Moreno Gonzalez
Glioblastomas, the most common and malignant brain tumors of the central nervous system, exhibit high invasive capacity, which hinders effective therapy. Therefore, intense efforts aimed at improved therapeutics are ongoing to delineate the molecular mechanisms governing glioma cell migration and invasion.
Abnormal expression of Pygopus 2 correlates with a malignant phenotype in hum...Enrique Moreno Gonzalez
Pygopus 2 (Pygo2) is a Pygo family member and an important component of the Wnt signaling transcriptional complex. Despite this data, no clinical studies investigating Pygo2 expression in lung cancer have yet been reported.
Differentiation of irradiation and cetuximab induced skin reactions in patien...Enrique Moreno Gonzalez
In order to improve the clinical outcome of patients with locally advanced squamous cell carcinoma of the head and neck (LASCCHN) not being capable to receive platinum-based chemoradiation, radiotherapy can be intensified by addition of cetuximab, a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR). The radioimmunotherapy with cetuximab is a feasible treatment option showing a favourable toxicity profile. The most frequent side effect of radiotherapy is radiation dermatitis, the most common side effect of treatment with cetuximab is acneiform rash. Incidence and severity of these frequent, often overlapping and sometimes limiting skin reactions, however, are not well explored. A clinical and molecular differentiation between radiogenic skin reactions and skin reactions caused by cetuximab which may correlate with outcome, have never been described before.
Cholestasis induces reversible accumulation of periplakin in mouse liverEnrique Moreno Gonzalez
Periplakin (PPL) is a rod-shaped cytolinker protein thought to connect cellular adhesion junctional complexes to cytoskeletal filaments. PPL serves as a structural component of the cornified envelope in the skin and interacts with various types of proteins in cultured cells; its level decreases dramatically during tumorigenic progression in human epithelial tissues. Despite these intriguing observations, the physiological roles of PPL, especially in noncutaneous tissues, are still largely unknown. Because we observed a marked fluctuation of PPL expression in mouse liver in association with the bile acid receptor farnesoid X receptor (FXR) and cholestasis, we sought to characterize the role of PPL in the liver and determine its contributions to the etiology and pathogenesis of cholestasis.
Functional p53 is required for rapid restoration of daunorubicin-induced lesi...Enrique Moreno Gonzalez
This document summarizes a research article that studied the role of p53 in daunorubicin (DNR)-induced lesions in the spleen. The key findings were:
1) DNR treatment caused more rapid cell death and weight loss in the spleens of wild type mice compared to p53-null mice.
2) While wild type mouse spleens recovered normal morphology 8 days after DNR treatment, p53-null mouse spleens still had large necrotic lesions.
3) DNR treatment increased p21 levels in wild type mice but not p53-null mice, indicating p53 is required for p21 induction.
4) The results suggest p53
Post-diagnosis hemoglobin change associates with overall survival of multiple...Enrique Moreno Gonzalez
Anemia refers to low hemoglobin (Hb) level and is a risk factor of cancer patient survival. The National Comprehensive Cancer Network recently suggested that post-diagnosis Hb change, regardless of baseline Hb level, indicates the potential presence of anemia. However, there is no epidemiological study evaluating whether Hb change has direct prognostic values for cancer patients at the population level.
Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation car...Enrique Moreno Gonzalez
Women with mutations in BRCA1 or BRCA2 are at high risk of developing breast cancer and, in British Columbia, Canada, are offered screening with both magnetic resonance imaging (MRI) and mammography to facilitate early detection. MRI is more sensitive than mammography but is more costly and produces more false positive results. The purpose of this study was to calculate the cost-effectiveness of MRI screening for breast cancer in BRCA1/2 mutation carriers in a Canadian setting.
Impaired mitochondrial beta-oxidation in patients with chronic hepatitis C: r...Enrique Moreno Gonzalez
Hepatic steatosis is often seen in patients with chronic hepatitis C (CH-C). It is still unclear whether these patients have an impaired mitochondrial β-oxidation. In this study we assessed mitochondrial β-oxidation in CH-C patients by investigating ketogenesis during fasting.
Intraepithelial lymphocyte distribution differs between the bulb and the seco...Enrique Moreno Gonzalez
Evaluation of intraepithelial duodenal lymphocytosis (IDL) is important in celiac disease (CD). There is no established cut-off value for increased number of IELs in the bulb. We therefore investigated the relation between IEL counts in the bulb and duodenal specimens in non-celiac subjects.
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Does Over-Masturbation Contribute to Chronic Prostatitis.pptxwalterHu5
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
2. Psychiatric treatment considerations with direct
acting antivirals in hepatitis C
Sanjeev Sockalingam1,2,*
Email: sanjeev.sockalingam@uhn.ca
Alice Tseng3,4
Email: alice.tseng@uhn.ca
Pierre Giguere5,6
Email: pgiguere@ottawahospital.on.ca
David Wong7,8
Email: dave.wong.uhn@gmail.com
1
University Health Network, Program in Medical Psychiatry, Toronto General
Hospital, 200 Elizabeth Street 8EN-228, Toronto, ON M5G 2C4, Canada
2
Department of Psychiatry, University of Toronto, Toronto, ON, Canada
3
University Health Network, Immunodeficiency Clinic, Toronto, ON, Canada
4
Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
5
The Ottawa Hospital, Immunodeficiency Clinic, Ottawa, ON, Canada
6
The Ottawa Hospital Research institute, Ottawa, ON, Canada
7
Toronto Western Hospital Liver Centre, Toronto, ON, Canada
8
Faculty of Medicine, University of Toronto, Toronto, ON, Canada
*
Corresponding author. University Health Network, Program in Medical
Psychiatry, Toronto General Hospital, 200 Elizabeth Street 8EN-228, Toronto,
ON M5G 2C4, Canada
Abstract
Background
Despite recent advances in hepatitis C (HCV) treatment, specifically the addition of direct
acting antivirals (DAAs), pegylated interferon-alpha remains the backbone of HCV therapy.
Therefore, the impact of DAAs on the management of co-morbid psychiatric illness and
neuropsychiatric sequalae remains an ongoing concern during HCV therapy. This paper
provides a review of the neuropsychiatric adverse effects of DAAs and drug-drug interactions
(DDIs) between DAAs and psychiatric medications.
3. Methods
We conducted a Pubmed search using relevant search terms and hand searched reference lists
of related review articles. In addition, we searched abstracts for major hepatology
conferences and contacted respective pharmaceutical companies for additional studies.
Results
Limited data is available on the neuropsychiatric adverse effects of DAAs; however, data
from major clinical trials suggest that DAAs have minimal neuropsychiatric risk. DAAs can
potentially interact with a variety of psychotropic agents via cytochrome P450 and p-
glycoprotein interactions. Triazolam, oral midazolam, St. John’s Wort, carbamazepine and
pimozide, are contraindicated with DAAs. DDIs between DAAs and antidepressants,
anxiolytics, hypnotics, mood stabilizers, antipsychotics and treatments for opioid dependence
are summarized.
Conclusions
Although DAAs do not add significant neuropsychiatric risk, the potential for DDIs is high.
Consideration of DDIs is paramount to improving medication adherence and mitigating
adverse effects during HCV therapy.
Keywords
Hepatitis C, Mental disorders, Psychotropic drugs, Boceprevir, Telaprevir
Background
Treatment of hepatitis C virus (HCV), a virus infecting over 170 million worldwide [1], has
evolved over the last two decades and moved from interferon-alpha monotherapy to
pegylated interferon-alpha (IFNα) in combination with ribavirin therapy. HCV therapy with
IFNα and ribavirin has yielded overall sustained virological response (SVR) rates of
approximately 54% to 56% with SVR rates for genotype 1 approximating 45% to 50% [2,3].
The next generation of HCV therapeutic agents is direct acting antivirals (DAAs) that still
require the use of interferon-ribavirin combination therapy. Protease inhibitors, specifically
telaprevir or boceprevir, in combination with IFNα and ribavirin (i.e. triple therapy) have
improved SVR rates to 70% to 75% in HCV genotype 1 patients [4,5].
Despite these enhanced SVR rates, psychiatric illness remains a barrier to widespread HCV
treatment uptake due to the neuropsychiatric risks associated with IFNα. It is estimated that
up to 50% of patients with untreated chronic HCV suffer from psychiatric illness when
substance abuse and dependence is excluded [6,7]. Lifetime rates of mood, anxiety and
personality disorders in untreated HCV-infected patients have each ranged from
approximately 20% to 40% [6,7]. Treatment with pegylated interferon-alpha (IFNα) therapy
can induce a myriad of neuropsychiatric side effects including depression in approximately
25% to 30% of patients undergoing IFNα therapy for HCV [8-11]. In addition, HCV-infected
patients with pre-existing psychiatric disorders may experience an exacerbation of
psychopathology secondary to IFNα.
4. Poorly managed psychiatric illness can lead to treatment discontinuation, poor adherence to
treatment and serious psychiatric sequalae, such as suicide [12,13]. The onset of suicidal
ideation and suicide on HCV therapy coincides with the onset of IFNα-induced depression
(IFNα-D) and requires prompt recognition and treatment to prevent these serious psychiatric
sequelae [12,14]. Integrated Hepatology-psychiatric care models have demonstrated the
capacity to mitigate neuropsychiatric risks associated with HCV therapy through improved
access to psychiatric and psychological interventions [15,16].
In the era of DAAs, adherence is paramount to treatment success given the strict dosing
regimen of first generation HCV protease inhibitors (PIs). First generation DAAs have high
pill burdens and frequent dosing intervals. Active depression has been associated with poor
antiviral therapy (ART) in patients infected with human immunodeficiency virus (HIV) [17].
Therefore, it is possible that poorly controlled psychiatric illness may compromise adherence
to PI dosing schedules and as a result, reduce HCV treatment efficacy. Similar to the advent
of HIV ART, first generation DAAs have also presented concerns regarding drug-drug
interactions (DDIs) with medications including several psychotropic medications. Given the
high prevalence of psychiatric illness in HCV-infected patients and need for psychotropic
treatments for IFNα-induced neuropsychiatric side effects, an understanding of salient DDIs
involving psychotropic medications is essential to the clinical care of patients treated for
HCV.
With respect to DDIs, both boceprevir and telaprevir are substrates and inhibitors of CYP3A4
[18,19]. Both agents also inhibit p-glycoprotein [18,19] and telaprevir may inhibit renal
transporters [20]. Approximately 50% to 60% of available prescription medications are
metabolized via CYP3A4 pathway [21,22]. Moreover, preliminary HCV data suggests that in
clinical practice, 72% of patients had at least one DDI and 50% had at least two DDIs related
to DAAs [23]. Therefore, there is a high potential for DDIs with HCV protease inhibitors,
particularly if treatment for other comorbid conditions is necessary.
Interactions may be pharmacokinetic or pharmacodynamic in nature. Pharmacodynamic
interactions impact drug efficacy or toxicity in an additive, synergistic or antagonistic
manner. For instance, pegylated interferon and ribavirin have CNS effects that overlap with
those of the antiretroviral regimens involving efavirenz; co-administration may theoretically
contribute to adverse effects including depression, mood changes, and suicidality. Clinicians
may therefore wish to avoid this combination if possible, particularly in patients with a
history of significant mental illness.
Pharmacokinetic interactions may result in altered concentrations of one or more interacting
drugs. Negative two-way interactions have been observed between both boceprevir and
telaprevir and ritonavir-boosted HIV protease inhibitors, with significant reductions in
exposures of HCV agents and HIV protease inhibitors; therefore, telaprevir should not be
coadministered with ritonavir-boosted darunavir, fosamprenavir, or lopinavir [18] and
boceprevir is not recommended for use with any boosted protease inhibitor [24].
Negative consequences of drug interactions may include viral breakthrough and development
of resistance, sub-optimal disease/symptom management, or drug toxicity and possible non-
adherence [25]. These interactions highlight the challenges of managing multiple
comorbidities in patients with HCV infection.
5. The purpose of this review was to evaluate the current evidence on: (i) the neuropsychiatric
adverse effects of DAAs, and (ii) the DDIs between DAAs and psychotropic agents when
used in HCV patients.
Methods
We performed a Pubmed search using MeSH headings “hepatitis C” AND “boceprevir” OR
“telaprevir” combined with “mental disorders”, “psychotropic drugs” and “drug interactions”.
We limited our search to English language studies published between 2000-April 2013.
References for all review articles were searched for additional studies as well as conference
abstracts. Additional information on psychiatric adverse effects and DDIs with DAAs were
requested from Vertex and Merck. Due to the limited literature, data on psychiatric adverse
effects was also obtained from registration trials for boceprevir and telaprevir. Theoretical
drug interactions were included in the respective sections. Due to available data on
antidepressant efficacy in depressed HCV populations, we discussed potential DAA and
antidepressant DDI in the context of clinical evidence for specific antidepressant agents for
treating depression during HCV therapy. Level of evidence was derived from 2 recent
guidelines and existing reviews [26-29] and a previously published grading system [30] was
used classify evidence for only studies examining antidepressant treatment of depression
during HCV therapy.
Results
Neuropsychiatric side effects of DAAs
Data on neuropsychiatric adverse effects of DAAs is limited and predominantly derived from
landmark clinical trials for boceprevir and telaprevir (see Table 1) [4,5,31-34]. Across trials,
there was no significant difference in neuropsychiatric side effects between DAAs and
treatment with peg- IFNα and ribavirin alone. It should be noted that the rates of
neuropsychiatric sequalae from DAAs may be an underestimate, as patients with significant
psychiatric illness were excluded from these studies and detection of psychiatric side effects
did not utilize formal psycho-diagnostic tools. Only one study published data on anxiety
during triple therapy and found a comparable reported rate of anxiety in patients treated with
triple therapy (10%) versus standard therapy alone (12%) [4]. Although studies focusing
specifically on psychiatric complications of DAAs are lacking, this preliminary data suggests
that DAAs confer a minimal risk of additional neuropsychiatric side effects.
6. Table 1 Psychiatric adverse effects in DAAs
Telaprevir Trials Boceprevir Trials
ADVANCE
[4]
ILLUMINATE*
[31]
REALIZE
[32]
SPRINT-1
[33]
SPRINT-2
[5]
RESPOND-2
[34]
Psychiatric Side
Effect
Fatigue 57% (57%) 68% 55% (40%) 68% (55%) 53% (60%) 54% (50%)
Insomnia 32% (31%) 31% 26% (26%) 28% (38%) 33% (32%) 30% (20%)
Irritability 22% (18%) - 14% (16%) - 22% (24%) 19% (13%)
Depression 18% (22%) - 9% (14%) - 23% (22%) 12% (15%)
Anxiety 10% (12%) - - - - -
% - percent for study arm corresponding to current standard of care for DAA.
(%) – percent for pegylated IFNα and Ribavirin treatment arm.
*ILLUMINATE – did not have pegylated IFNα and Ribavirin treatment arm.
Antidepressant use with DAAs
Antidepressants are used primarily in the treatment of depression and anxiety in both
untreated HCV patients and patients undergoing IFNα therapy for HCV. Studies have
explored the use of antidepressants in HCV as both prophylactic (i.e. antidepressant pre-
treatment) and symptomatic treatment for IFNα-D. Two recent guidelines have specifically
identified management of IFNα-D and provided recommendations for antidepressant therapy
in HCV-infected patients (see Table 2). Based upon these guidelines and previous reviews
[26], only escitalopram currently has Level 1 evidence for treating or preventing depression
emerging during HCV treatment [35,36].
7. Table 2 Evidence for antidepressant treatment of depression during HCV Therapy and
drug interactions with DAAs
Level of
Evidence for
Depression
Treatment
Antidepressant (route of
metabolism)
Known or Potential Interactions with
DAAs
Comments
Level 1 Escitalopram (CYP2C19, 3A4 >>
2D6)
No interaction observed with boceprevir
[37] 35% ↓ escitalopram AUC with
telaprevir [38]
Boceprevir: no dose
adjustment required.
Telaprevir: May need to
titrate escitalopram dose
according to clinical
response.
Level 2 Citalopram (CYP2C19, 3A4 >>
2D6)
Potential for ↓ antidepressant
concentrations based on escitalopram
interaction data.
Monitor and titrate dose
according to clinical
response.
Paroxetine* (CYP2D6) No interaction expected based on known
pharmacologic characteristics.
Monitor and titrate dose
according to clinical
response.
Level 4 Bupropion (CYP2B6) Fluoxetine
(CYP2D6)
No interaction expected based on known
pharmacologic characteristics.
Monitor and titrate dose
according to clinical
response.
Sertraline (CYP2B6 > 2C9/19, 3A4,
2D6, UGT1A1 - possible)
Mirtazapine (CYP2D6, 1A2, 3A4)
Venlafaxine (CYP2D6 > CYP3A4)
Potential for ↑ sertraline, mirtazapine,
venlafaxine concentrations (clinical
significance unknown).
Use with caution;
monitor and titrate dose
according to clinical
response.
Desvenlafaxine (UGT>>3A4)
[39,40]
Potential for ↑ desvenlafaxine
concentrations (clinical significance
unknown).
Monitor and titrate
antidepressant dose
according to clinical
response.
Tricyclic antidepressants i.e.
desipramine (CYP2D6>>UGT),
imipramine (CYP2D6, 1A2, 2C19,
3A > UGT), trazodone**
(CYP2D6> CYP3A)
Potential increase in TCA concentrations
resulting in dizziness, hypotension and
syncope.
Use with caution with
DAAs, lower TCA
doses are recommended.
Nortriptyline (CYP2D6) No interaction expected based on known
pharmacologic characteristics.
Monitor and titrate dose
according to clinical
response.
Avoid
(exceptional
circumstances
only)
Duloxetine (CYP1A2, 2D6) Duloxetine: risk of hepatotoxicity. Duloxetine is
contraindicated in liver
disease.
Nefazodone (CYP3A4) Nefazodone: potential for ↑ nefazodone
and/or DAA concentrations; also risk of
hepatotoxicity.
Nefazone was
discontinued in the
United States and
Canada in 2003 due to
hepatotoxicity concerns.
Avoid use in liver
disease.
St. John’s Wort (hypericum
perforatum); induces CYP3A4 and
P-gp [40].
Potential for ↓ DAA concentrations. St. John’s Wort is
contraindicated with
boceprevir [19]and
telaprevir [18].
*Evidence in RCT for depressed mood component of major depression only.
**Trazodone is primarily used clinically for treating insomnia.
Level of Evidence: Level I (≥ 2 RCTs or meta-analysis), Level 2 (1 RCT), Level 4 (Case
reports/series or expert opinion).
8. Anxiety secondary to IFNα can also be treated with antidepressants, which are a first line
treatment based upon the limited available literature (Level 4) [41,42]. Escitalopram and
citalopram may be beneficial options in treating anxiety disorders in HCV based upon the
anecdotal reports of safety in HCV [43-45] and extrapolation of evidence from non-HCV
anxiety treatment guidelines [46]. Clinicians should be aware of the potential risk of dose-
related QT prolongation with citalopram and escitalopram [47]. The maximum recommended
dose is citalopram 20 mg per day in patients with hepatic impairment, those 65 years of age
or older, patients who are CYP2C19 poor metabolizers, or patients who are taking
concomitant cimetidine or another CYP2C19 inhibitor [48]. In some countries, such as
Canada, the maximum recommended dose for escitalopram in patients with hepatic
impairment is 10 mg per day due to QT prolongation concerns [49].
Drug interactions between DAAs and some antidepressants, specifically those affected by
CYP 450 interactions of PIs, may lead to clinically significant adverse effects which impact
tolerability to therapy for HCV. For example, SSRIs and Selective Noradrenergic Reuptake
Inhibitors (SNRIs) can be associated with nausea, gastrointestinal upset, sweating and sexual
dysfunction, which could emerge with PI related drug interactions.
Specific drug interactions with antidepressants and DAAs are summarized in Table 2. In a
single study involving telaprevir, escitalopram area under the curve (AUC) was reduced by
35%, suggesting the need for clinicians to monitor the need for dose optimization on triple
therapy [50]. No significant DDI has been observed between escitalopram and boceprevir
[37]. Specific antidepressants, for example trazodone, that have a high sedative potential and
potential for DDIs with DAAs can lead to increased sedation and may impact overall
tolerability and compliance to both agents. Therefore, the selection of antidepressant agents
during HCV therapy should include consideration of potential DDIs, in order to avoid
possible adverse effects, which may negatively affect HCV antiviral treatment adherence.
Clinicians should also be aware that St. John’s Wort is a potent inducer of CYP3A4 and P-gp
[40], and is contraindicated with DAAs due to the potential risk for significant reductions in
boceprevir or telaprevir concentrations [18,19].
Benzodiazepine & hypnotic use with DAAs
Benzodiazepines may be a treatment option for anxiety symptoms in the context of HCV or
secondary to IFNα; however, no large trials have examined the efficacy of anxiolytics in
HCV [16,41,42,51,52]. Anecdotally, benzodiazepines have also been used short-term for
insomnia in HCV-infected patients [41]. Furthermore, the prevalence of substance
dependence in HCV patients has cautioned the use of benzodiazepines in this patient
population. In general, short-acting benzodiazepines should be avoided due to potential
rebound effect on anxiety and long-term benzodiazepine use may lead to tolerance and
dependence.
If benzodiazepines are used, lorazepam, oxazepam or temazepam are preferred due to the
reliance on glucuronidation, a process that is relatively preserved in patients with significant
liver disease [53]. Furthermore, these three agents are the least susceptible to
pharmacokinetic interactions with DAAs since they are not metabolized through the
cytochrome P450 system. Most other benzodiazepine agents undergo metabolism solely or
partially through CYP3A4, and thus concentrations may be increased by DAAs via CYP3A4
inhibition. Triazolam and oral midazolam are contraindicated with boceprevir and telaprevir,
due to hypothesized or documented significant interactions. When administered orally,
9. midazolam exposures were increased 430% in the presence of boceprevir [54] and almost 9-
fold in the presence of telaprevir [55]. Intravenous midazolam concentrations increased 3.4-
fold when co-administered with telaprevir [55]. Thus, while intravenous midazolam is not
absolutely contraindicated with PIs, it is recommended that this combination be administered
with caution in a setting which allows for close clinical monitoring for prolonged sedation
and/or respiratory depression, and that dose adjustment of intravenous midazolam should be
considered [19].
Zolpidem is metabolized through a variety of CYP450 isozymes, including CYP3A, 2C9,
1A2, 2D6, and 2C19. In the presence of steady-state telaprevir, zolpidem exposures were
unexpectedly reduced by 47% [56]. Close monitoring and dose titration of zolpidem is
recommended if this agent is coadministered with telaprevir. Zopiclone is also metabolized
predominantly by CYP3A4 and to a lesser degree by CYP2C8 and CYP2C9. Zopiclone
concentrations may theoretically be increased by DAAs and require close monitoring. Most
other benzodiazepines should be used cautiously in patients on DAAs. Clinicians may
consider starting with a decreased benzodiazepine dose and monitoring for benzodiazepine-
related toxicity, or selecting an alternate agent such as lorazepam, oxazepam or temazepam.
Dose reductions are also recommended in patients with severe liver impairment as per
product monographs [18,19].
Anticonvulsant use with DAAs
Anticonvulsants can be used as mood stabilizers for new onset or de-stabilized bipolar
disorder during IFNα therapy for HCV. Studies on the efficacy of anticonvulsants as
moodstabilizers in HCV are limited to case reports and as a result, treatment often follows
non-HCV bipolar treatment guidelines [30].
Lithium is a preferred moodstabilizer due its renal excretion and minimal dose adjustment in
patients with HCV except in patients with shifting fluid balance resulting from
decompensated cirrhosis [57]. Lithium has no known drug interactions with DAAs. Valproic
acid has no significant DDIs with DAAs; however, valproic acid use in HCV has been
limited by its purported risk of hepatotoxicity [58]. Nonetheless, in a study of patients with
less severe HCV disease, elevations in alanine aminotransferase (ALT) were comparable
between valproic acid and other psychotropic agents [59].
Amongst the remaining moodstabilizers, carbamazepine is contraindicated due to induction
of cytochrome P450 3A4 and potential for decreasing boceprevir or telepravir levels (see
Table 3). Lamotrigine undergoes extensive metabolism by UDP-glucuronosyltransferase
(UGT) 1A4 [60]. This metabolic pathway is not inhibited or induced by boceprevir or
telaprevir. Lamotrigine has been associated with severe rash, including Steven’s Johnson
rash. Given that DAAs, particularly telaprevir, have also been associated with severe rashes,
it is recommended to use extra precautions if coadministration is required. Gabapentin and
pregabalin are not effective moodstabilizers for bipolar disorder in monotherapy [61];
however, based upon data from non-HCV populations pregabalin and gabapentin can be
efficacious in treating co-morbid generalized anxiety disorder (GAD) in HCV. Both
pregabalin and gabapentin have no significant drug interactions with HCV triple therapy
involving DAAs as they are both predominantly renally excreted. Table 3 provides a
summary of anticonvulsant drug interactions with DAAs.
10. Table 3 Anticonvulsant drug interactions with DAAs
Drug (route of metabolism) Known or Potential Interactions with
DAAs
Comments
Lithium (renal) No interaction expected based on known
pharmacologic characteristics
Monitor and titrate dose
according to clinical response
and serum levels.
Valproic Acid, divalproex
Parent: UGT (50%), minor
CYP dependent oxidation
pathway (<10%) Inhibitor of
UGT,CYP2C9/19
No interaction expected based on known
pharmacologic characteristics
Monitor and titrate dose
according to clinical response
and serum levels.
Carbamazepine Parent:
CYP3A>> 2C8, 1A2 Inducer
of CYP3A, 2C9, 2C19, UGT
and possibly 1A2
Potential for ↓ DAAs concentrations Carbamazepine is
contraindicated with boceprevir
[19] Co-administration of
telaprevir with potent CYP3A4
inducers such as carbamazepine
may lead to reduced DAA
plasma concentrations and
decreased efficacy [18]
Carbamazepine clearance can
also potentially be decreased
[62]. Consider an alternate agent
with non-inducing metabolic
properties.
Oxcarbazepine Parent: UGT
Inhibitor of CYPC19 Potent
inducer of CYP3A4. Relative
to carbamazepine,
oxcarbazepine inducing effect
is 54% lower [63]
Potential for ↓ DAAs concentrations Co-administration of boceprevir
and telaprevir with potent
CYP3A4 inducers, may lead to
reduced DAA plasma
concentrations and decreased
efficacy. Consider an alternate
agent with non-inducing
metabolic properties [64].
Lamotrigine (UGT) No interaction expected based on known
pharmacologic characteristics
Monitor and titrate dose
according to clinical response.
Gabapentin (Renal) No interaction expected based on known
pharmacologic characteristics
Monitor and titrate dose
according to clinical response.
Pregabalin (Renal) No interaction expected based on known
pharmacologic characteristics
Monitor and titrate dose
according to clinical response.
Antipsychotic use with DAAs
Antipsychotic medications can be used during HCV therapy to stabilize pre-existing mood or
psychotic disorders in patients or to treat IFNα-induced mood or psychotic symptoms
secondary. Patients with severe mental illness, such as schizophrenia [65,66] and bipolar
disorder [67] have been shown to have higher rates of HCV compared to the general
population and thus, it may not be uncommon to treat patients with HCV who are already
treated with antipsychotic medications for severe mental illness. Albeit rare, antipsychotic
medications may be used to treat de novo secondary to IFNα [68-72]. In addition, atypical
antipsychotics can be used for mood stabilization and irritability emerging during HCV
therapy [41,73,74].
11. Several DDIs and side effects should be considered when prescribing antipsychotic
medication in the context of HCV triple therapy (see Table 4). Telaprevir and boceprevir may
interact with antipsychotics prone to corrected QT (QTc) interval prolongation and elevations
in plasma levels could increase QTc prolongation risk. As a result, pimozide, a conventional
antipsychotic with a high propensity for QTc prolongation, is contraindicated when treating
patients with boceprevir and telaprevir. Amongst the atypical antipsychotics, ziprasidone,
which is metabolized by CYP 3A4, is associated with an increased QTc prolongation risk
amongst novel antipsychotics [75]. Initiation of ziprasidone should include a baseline
electrocardiogram (ECG) and this may need to be reassessed on triple therapy for HCV due
to DDI.
Table 4 Antipsychotic drug interactions with DAAs
Drug (route of metabolism) Known or Potential Interactions
with DAAs
Comments
Aripiprazole (CYP3A4, 2D6) Potential for ↑ aripiprazole
concentrations
Use combination with caution,
and monitor for aripiprazole-
related toxicity (sedation, sinus
tachycardia, nausea/vomiting,
or dystonic reactions).
Consider starting with a
decreased aripiprazole dose or
select an alternate agent.
Asenapine (UGT1A4,
CYP1A2)
No interaction expected based on
known pharmacologic characteristics
Monitor and titrate dose
according to clinical response
[76].
Clozapine (CYP1A2> 3A4,P-
gp)
Potential for ↑ clozapine
concentrations
Clozapine has a narrow
therapeutic index. Use
combination with caution, and
monitor for clozapine-related
toxicity (Bone marrow
suppression, generalized
seizures, severe sedation,
confusion and delirium).
Consider starting with a
decreased clozapine dose or
select an alternate agent. When
available, clozapine therapeutic
drug monitoring is
recommended [77,78].
Olanzapine (CYP1A2,
UGT,PGP>2D6)
No interaction expected based on
known pharmacologic characteristics
Monitor and titrate dose
according to clinical response.
Paliperidone Primarily renally
excreted (59%); minor CYP
dependant pathway (CYP3A4,
PGP>2D6), but may not be
clinically significant. Substrate
and inhibitor of P-gp [79]
Potential for ↑ paliperidone
concentrations
DAAs inhibit both CYP3A4
and P-gp, and clinically
significant interaction,
although unlikely, cannot be
ruled out. Use combination
with caution, and monitor for
possible paliperidone-related
toxicity.
12. Quetiapine (CYP3A4>2D6, P-
gp)
Potential for ↑ quetiapine
concentrations
Use combination with caution,
and monitor for quetiapine-
related toxicity (excessive
sedation). Consider starting
with a decreased quetiapine
dose or select an alternate agent
[80].
Risperidone (CYP2D6, P-
gp>3A4)
Potential for ↑ risperidone
concentrations
Unlike its active metabolite
paliperidone, risperidone is
primarily metabolized by
CYP2D6. However, the
elimination of paliperidone
may be impaired. Use
combination with caution, and
monitor for possible
risperidone-related toxicity.
Ziprasidone (CYP3A4>1A2)
Minor CYP dependant
pathway(33%) [78].
Potential for ↑ ziprasidone
concentrations
Although clinically significant
interaction unlikely, use
combination with caution, and
monitor for possible
ziprasidone-related toxicity
(QTc).
Several antipsychotics are metabolized via CYP3A4/5, which are inhibited by current DAAs.
Sedating antipsychotics that are metabolized by CYP3A4, such as quetiapine, may be
increased via DDIs secondary to DAAs and could result in more pronounced sedation that
could hinder compliance with multiple daily dosing regimens of DAAs. Clozapine is also
metabolized in part by CYP3A4 and clozapine levels should be monitored closely during
HCV triple therapy as higher doses of clozapine have been associated with an increased
adverse effects including seizures [81]. Treatment with clozapine is further complicated
during HCV therapy due to additive theoretical risks of agranulocytosis and neutropenia
related specifically to IFNα effects. Therefore, clozapine monitoring protocols may need to
be adjusted due to this risk and vigilant follow-up monitoring for signs of infection is
recommended [82].
Lastly, DAAs are known inhibitors of P-gp and many second generation antipsychotics are
substrates of P-gp [83]. In theory, inhibition of P-gp may lead to increased exposure of the
antipsychotic in the CSF, and may be associated with enhanced effectiveness or toxicity [79].
Despite the absence of documented metabolic drug interactions, caution is to be exercised
with known substrates of P-gp (quetiapine, risperidone, olanzapine) and DAAs.
Addictions agents with DAAs
Given the higher rates of substance dependence in HCV-infected patient populations
compared to the general population [6], treatment of concurrent substance use disorders,
either through harm reduction or abstinence based models, is an important component of pre-
HCV therapy stabilization. To date, no studies have determined if the addition of DAAs to
HCV treatment increased the risk of substance use relapse.
In some HCV-infected populations, methadone treatment is a core component of HCV
treatment stabilization in patients at risk of opioid and polysubstance dependence [84,85].
13. Methadone is metabolized by CYP2C19 and 3A4. The coadministration of methadone and
telaprevir was shown to result in a 21% decrease of the active enantiomer R-methadone
exposure [86]. However, free concentrations of R-methadone were unaffected and therefore
no dosage adjustment is necessary. Buprenorphine pharmacokinetics are not affected by
telaprevir and is safe for coadministration [87]. Boceprevir was studied with methadone,
buprenorphine and naloxone. Similar to telaprevir, boceprevir led to a 15% decrease of R-
methadone exposure. No free methadone concentrations were performed. Boceprevir was
also associated with an increase of naloxone and buprenorphine exposure by 19 and 33%
respectively, which is considered to be clinically non-significant [88].
Discussions
Psychiatric disorders are highly prevalent in patients infected with chronic HCV and until
IFNα-free therapies for HCV emerge, it is evident that neuropsychiatric risks of HCV therapy
continue to be a significant concern. This review provides further information on the impact
of DAAs on the neuropsychiatric sequelae of HCV therapy and clarifies the potential for
DDIs with psychotropic medications.
First, DAAs do not appear to confer additional neuropsychiatric risks to patients undergoing
HCV triple therapy. However, the use of DAAs warrants careful recognition of potential
DDIs with psychotropic agents and an analysis of whether psychotropic regimens should be
changed due to significant DDI risks. In addition, the potential for DDIs with psychotropic
agents may exacerbate side effects and may interfere with DAA compliance, thus reducing
HCV treatment efficacy.
The potential for clinically significant and complex interactions between DAAs and
psychotropic drug classes is high. Interactions are primarily pharmacokinetic in nature, and
may result in increased or decreased exposures of either/both drug classes. Potential clinical
consequences of such interactions may include increased toxicity or potential under dosing.
In the case of DAAs, sub-therapeutic concentrations may lead to treatment failure and
development of resistance. Whenever possible, non-essential medications should be
discontinued for the duration of HCV treatment.
Steps to identifying and managing interactions include ensuring that medication records are
up to date at each patient visit (i.e., medication reconciliation), use of a systematic approach
to identify combinations of potential concern, consulting pertinent HCV drug interaction
resources, and frequent patient monitoring. Other management options include altering
dosing frequency or replacing one agent with another drug with lower interaction potential.
Given the complexity of this field, clinicians are encouraged to consult with pharmacists or
physicians with expertise in HCV pharmacology when managing drug therapy of co-infected
patients.
The results of this review can be beneficial in informing the selection of psychotropic agents
for common psychiatric presentations in HCV. Using self-report or clinician rated psychiatric
scales to measure treatment response to pharmacotherapy can be beneficial in monitoring
relapse following psychotropic dose adjustments due to DDIs. For example, both the Beck
Depression Inventory-II [89] or Patient Health Questionnaire-9 [87] for depression have been
used and validated in this patient population. Further, awareness and education of the entire
interdisciplinary treatment team is important in order to assist with prompt recognition of
14. psychiatric symptoms, appropriate selection of psychotropic agents with minimal drug
interactions and to minimize adverse effects to increased overall treatment adherence. The
importance of interdisciplinary models of HCV care is evident from studies showing
comparable HCV treatment adherence rates and outcomes for patients with either active
substance use [84,90] or severe mental illness [91,92] as compared to controls.
Conclusions
In summary, this review summarizes the emerging body of evidence in this area but also
acknowledges the remaining gaps in the literature. Studies utilizing more detailed psychiatric
assessment tools during HCV treatment with DAAs are needed to increase our understanding
of DAA related psychiatric complications. Additional drug interaction studies between DAAs
and commonly used psychotropic agents are urgently needed. The results of these studies will
be essential to guiding clinicians presented with challenges in interpreting DDI risks related
to psychiatric care in the era of HCV triple therapy, in order to optimize HCV treatment
outcomes and as well as management of psychiatric symptomatology.
Competing interest
The authors have no funding interest to declare with respect to this study.
Authors’ contribution
SS has served as a speaker for Roche Canada. AT has received honoraria for consulting work
with Merck- Canada and Vertex Pharmaceuticals. PG has served as a speaker, a consultant
and an advisory board member for Vertex Pharmaceuticals and Merck Frosst Canada. DKW
has received nursing support from Roche Canada and Shering-Plough Canada. All authors
read and approved the final manuscript.
References
1. Wasley A, Alter MJ: Epidemiology of hepatitis C: geographic differences and
temporal trends. Semin Liver Dis 2000, 20(1):1–16.
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D,
Diago M, Carosi G, Dhumeaux D, et al: Peginterferon alfa-2a plus ribavirin for chronic
hepatitis C virus infection. N Engl J Med 2002, 347(13):975–982.
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R,
Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin
compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis
C: a randomised trial. Lancet 2001, 358(9286):958–965.
4. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH,
Marcellin P, Muir AJ, Ferenci P, Flisiak R, et al: Telaprevir for previously untreated
chronic hepatitis C virus infection. N Engl J Med 2011, 364(25):2405–2416.
15. 5. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM,
Reddy KR, Goodman ZD, Boparai N, et al: Boceprevir for untreated chronic HCV
genotype 1 infection. N Engl J Med 2011, 364(13):1195–1206.
6. El-Sarag HB, Kunik M, Richardson P, Rabaneck L: Psychiatric disorders among
veterans with hepatitis C infection. Gastroenterology 2002, 123:476–482.
7. Yovtcheva SP, Rifai MA, Moles JK, Linden BJV: Psychiatric comorbidity among
hepatitis C-positive patients. Psychosomatics 2001, 42:411–415.
8. Horikawa N, Yamazaki T, Izumi N, Uchihara M: Incidence and clinical course of major
depression in patients with chronic hepatitis type C undergoing interferon-alpha
therapy: a prospective study. Gen Hosp Psych 2003, 25:34–38.
9. Morasco BJ, Loftis JM, Indest DW, Ruimy S, Davison JW, Felker B, Hauser P:
Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy:
a double-blind, placebo-controlled trial. Psychosomatics 2010, 51(5):401–408.
10. Morasco BJ, Rifai MA, Loftis JM, Indest DW, Moles JK, Hauser P: A randomized trial
of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis
C. J Affect Disord 2007, 103:83–90.
11. Hauser P, Khosla J, Aurora H, Laurin J, Kling MA, Hill J, Gulati M, Thornton AJ,
Schultz RL, Valentine AD, et al: A prospective study of the incidence and open-label
treatment of interferon-induced major depressive disorder in patients with hepatitis C.
Mol Psychiatry 2002, 7(9):942–947.
12. Dieperink E, Ho SB, Tetrick L, Thuras P, Dua K, Willnebring ML: Suicidal ideation
during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C.
Gen Hosp Psych 2004, 26:237–240.
13. Ademmer K, Beutel M, Bretzel R, Jaeger C, Reimer C: Suicidal ideation with IFN-
alpha and ribavirin in a patient with hepatitis C. Psychosomatics 2001, 42(4):365–367.
14. Sockalingam S, Links PS, Abbey SE: Suicide risk in hepatitis C and during
interferon-alpha therapy: a review and clinical update. J Viral Hepat 2011, 18(3):153–
160.
15. Schaefer M, Hintzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, Sarkar R,
Friebe A, Heinz A, Kluschke M, et al: Hepatitis C treatment in "difficult-to-treat"
psychiatric patients with pegylated interferon-alpha and ribavirin: response and
psychiatric side effects. Hepatology 2007, 46:991–998.
16. Neri S, Bertino G, Petralia A, Giancarlo C, Rizzotto A, Calvagno GS, Mauceri B, Abate
G, Boemi P, Di Pino A, et al: A multidisciplinary therapeutic approach for reducing the
risk of psychiatric side effects in patients with chronic hepatitis C treated with
pegylated interferon alpha and ribavirin. J Clin Gastroenterol 2010, 44(9):e210–217.
16. 17. Moore DJ, Blackstone K, Woods SP, Ellis RJ, Atkinson JH, Heaton RK, Grant I:
Methamphetamine use and neuropsychiatric factors are associated with antiretroviral
non-adherence. AIDS Care 2012, 24(12):1504–1513.
18. Vertex Pharmaceuticals Inc: Incivek (telaprevir) Product Monograph. Cambridge, MA:
Vertex Pharmaceuticals Incorporated; 2012.
19. Merck Canada Inc: Victrelis (boceprevir) Product Monograph. Kirkland, QC: Merck
Canada Inc; January 16, 2013.
20. Kunze A, Huwyler J, Camenisch G, Gutmann H: Interaction of the antiviral drug
telaprevir with renal and hepatic drug transporters. Biochem Pharmacol 2012,
84(8):1096–1102.
21. Guengerich FP: Cytochrome P450s and other enzymes in drug metabolism and
toxicity. AAPS J 2006, 8(1):E101–111.
22. Flockhart DA, Tanus-Santos JE: Implications of cytochrome P450 interactions when
prescribing medication for hypertension. Arch Intern Med 2002, 162(4):405–412.
23. Kipp G, Mohammad R, Lin A, Johnson H: Evaluation of pharmacist identified and
mitigated drug-drug interactions in hepatitis C virus infected patients starting
telaprevir or boceprevir. In The 63rd Annual Meeting of the American Association for the
Study of Liver Diseases. Boston, MA; 2012.
24. Hulskotte EGJ, Feng H-P, Xuan F, van Zutven M, O’Mara E, Youngberg S, Wagner JA,
Butterton JR: Pharmacokinetic interaction between the HCV protease inhibitor
boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, lopinavir, and
darunavir. Clin Infect Dis 2013, 56(5):718–726.
25. Marzolini C, Elzi L, Gibbons S, Weber R, Fux C, Furrer H, Chave JP, Cavassini M,
Bernasconi E, Calmy A, et al: Prevalence of comedications and effect of potential drug-
drug interactions in the Swiss HIV Cohort Study. Antivir Ther 2010, 15(3):413–423.
26. Sockalingam S, Abbey SE: Managing depression during hepatitis C treatment. Can J
Psychiatry 2009, 54(9):614–625.
27. Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, Foster GR,
Kautz A, Forton D, Pariante CM: Hepatitis C infection, antiviral treatment and mental
health: A European expert consensus statement. J Hepatol 2012, 57(6):1379–1390.
28. Ramasubbu R, Taylor VH, Saaman Z, Sockalingham S, Li M, Patten S, Rodin G,
Schaffer A, Beaulieu S, McIntyre RS: The Canadian Network for Mood and Anxiety
Treatments (CANMAT) task force recommendations for the management of patients
with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry 2012,
24(1):91–109.
29. Baraldi S, Hepgul N, Mondelli V, Pariante CM: Symptomatic treatment of interferon-
alpha-induced depression in hepatitis C: a systematic review. J Clin Psychopharmacol
2012, 32(4):531–543.
17. 30. Yatham LN, Kennedy SH, Schaffer A, Parikh SV, Beaulieu S, O'Donovan C, MacQueen
G, McIntyre RS, Sharma V, Ravindran A, et al: Canadian Network for Mood and Anxiety
Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD)
collaborative update of CANMAT guidelines for the management of patients with
bipolar disorder: update 2009. Bipolar Disord 2009, 11(3):225–255.
31. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried
MW, Adler M, Reesink HW, Martin M, et al: Response-guided telaprevir combination
treatment for hepatitis C virus infection. N Engl J Med 2011, 365(11):1014–1024.
32. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z,
Foster GR, Horban A, et al: Telaprevir for retreatment of HCV infection. N Engl J Med
2011, 364(25):2417–2428.
33. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS,
Gordon SC, Ravendhran N, et al: Efficacy of boceprevir, an NS3 protease inhibitor, in
combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with
genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre
phase 2 trial. Lancet 2010, 376(9742):705–716.
34. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F,
Goodman ZD, Sings HL, Boparai N, et al: Boceprevir for previously treated chronic HCV
genotype 1 infection. N Engl J Med 2011, 364(13):1207–1217.
35. Schaefer M, Sarkar R, Knop V, Effenberger S, Friebe A, Helnze L, Spengler U,
Schlaepfer T, Relmer J, Bugglsch P, et al: Escitalopram for the prevention of
peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients
without previous psychiatric disease. Ann Intern Med 2012, 157:94–103.
36. Gleason OC, Fucci JC, Yates WR, Philipsen MA: Preventing relapse of major
depression during interferon-alpha therapy for hepatitis C–A pilot study. Dig Dis Sci
2007, 52(10):2557–2563.
37. Hulskotte EGJ, Gupta S, Xuan F, van Zutven MGJA, O'Mara E, Galitz L, Wagner JA,
Butterton JR: Coadministration of the HCV protease inhibitor boceprevir has no
clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake
inhibitor escitalopram in healthy volunteers. Global Antiviral Journal 2011, 7(1):108–109.
abstract.
38. Van Heeswijk RPG, Boogaerts G, De Paepe E, Van Solingen-Ristea R, Garg V,
Beaumont M: The pharmacokinetic interaction between escitalopram and the
investigational HCV protease inhibitor telaprevir [abstract 12]. Rev Antiviral Ther Infect
Dis 2010, 5:12–13.
39. Nichols AI, Behrle JA, Parks V, Richards LS, McGrory SB, Posener J, Patat A, Paul J:
Pharmacokinetics, pharmacodynamics, and safety of desvenlafaxine, a serotonin-
norepinephrine reupatke inhibitor. J Bioequiv Availab 2013, 5:1.
40. Zhou SF, Lai X: An update on clinical drug interactions with the herbal
antidepressant St. John's wort. Current drug metabolism 2008, 9(5):394–409.
18. 41. Maddock C, Baita A, Orru MG, Sitzia R, Costa A, Muntoni E, Farci MG, Carpiniello B,
Pariante CM: Psychopharmacological treatment of depression, anxiety, irritability and
insomnia in patients receiving interferon-alpha: a prospective case series and a
discussion of biological mechanisms. J Psychopharmacol 2004, 18(1):41–46.
42. Dieperink E, Leskela J, Dieperink ME, Evans B, Thuras P, Ho SB: The effect of
pegylated interferon-alpha2b and ribavirin on posttraumatic stress disorder symptoms.
Psychosomatics 2008, 49(3):225–229.
43. Gleason OC, Yates WR, Philipsen MA, Isbell MD, Pollock BG: Plasma levels of
citalopram in depressed patients with hepatitis C. Psychosomatics 2004, 45(1):29–33.
44. Gleason OC, Yates WR, Isbell MD, Philipsen MA: An open-label trial of citalopram
for major depression in patients with hepatitis C. J Clin Psychiatry 2002, 63(3):194–198.
45. Gleason OC, Yates WR, Philipsen MA: Major depressive disorder in hepatitis C: an
open-label trial of escitalopram. Prim Care Companion J Clin Psychiatry 2005, 7(5):225–
230.
46. Swinson RP, Antony MM, Bleau P, Chokka P, Craven M, Fallu A, Katzman M,
Kjernisted K, Lanius R, Manassis K, et al: Clinical Practice Guidelines: Management of
Anxiety DIsorders. Can J Psychiatry 2006, 51(8):2.
47. Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Erb JL,
Churchill SE, Kohane IS, Iosifescu DV, et al: QT interval and antidepressant use: a cross
sectional study of electronic health records. BMJ 2013, 346:f288.
48. Lundbeck Canada Inc: Celexa (citalopram) Product Monograph. Montreal, QC:
Lundbeck Canada Inc; 2012.
49. Lundbeck Canada Inc: Cipralex (escitalopram) Product Monograph. Montreal, QC:
Lundbeck Canada Inc; 2012.
50. DeMaio W, Kane CP, Nichols AI, Jordan R: Metabolism studies of desvenlafaxine. J
Bioequiv Availab 2011, 3:151–160.
51. Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H: Psychiatric
symptoms related to interferon therapy for chronic hepatitis C: clinical features and
prognosis. Psychiatry Clin Neurosci 2000, 54:565–572.
52. Scalori A, Pozzi M, Bellia V, Apale P, Santamaria G, Bordoni T, Redaelli A, Avolio A,
Parravicini P, Pioltelli P, et al: Interferon-induced depression: prevalence and
management. Dig Liver Dis 2005, 37(2):102–107.
53. Huet PM, Villeneuve JP: Determinants of drug disposition in patients with cirrhosis.
Hepatology 1983, 3(6):913–918.
54. Kasserra C, Hughes E, Treitel M, Gupta S, O’Mara E: Clinical pharmacology of
boceprevir: metabolism, excretion, and drug-drug interactions [abstract 118]. In 18th
Conference on Retroviruses and Opportunistic Infections. Boston, USA; 2011.
19. 55. Garg V, Chandorkar G, Farmer HF, Smith F, Alves K, Van Heeswijk RPG: Effect of
telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol 2012,
52(10):1566–1573.
56. Luo X, Van Heeswijk RPG, Alves K, Garg V: The effect of telaprevir on the
pharmacokinetics of alprazolam and zolpidem in healthy volunteers [abstract PK_11].
Rev Antiviral Ther Infect Dis 2011, 6:13.
57. Rifai MA: Hepatitis C treatment of patients with bipolar disorder: a case series. Prim
Care Companion J Clin Psychiatry 2006, 8(6):361–366.
58. Powell-Jackson PR, Tredger JM, Williams R: Hepatotoxicity to sodium valproate: a
review. Gut 1984, 25(6):673–681.
59. Felker BL, Sloan KL, Dominitz JA, Barnes RF: The safety of valproic acid use for
patients with hepatitis C infection. Am J Psychiatry 2003, 160(1):174–178.
60. Argikar UA, Remmel RP: Variation in glucuronidation of lamotrigine in human liver
microsomes. Xenobiotica; the fate of foreign compounds in biological systems 2009,
39(5):355–363.
61. Schaffer A, McIntosh D, Goldstein BI, Rector NA, McIntyre RS, Beaulieu S, Swinson R,
Yatham LN: The CANMAT task force recommendations for the management of patients
with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry 2012, 24(1):6–
22.
62. Novartis Pharmaceuticals Canada Inc: Tegretol (Carbamazepine) Product Monograph.
Dorval, Que: Novartis Pharmaceuticals Canada Inc; 2011.
63. Andreasen AH, Brosen K, Damkier P: A comparative pharmacokinetic study in
healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4.
Epilepsia 2007, 48(3):490–496.
64. Hachad H, Ragueneau-Majlessi I, Levy RH: New antiepileptic drugs: review on drug
interactions. Ther Drug Monit 2002, 24(1):91–103.
65. Freudenreich O, Gandhi RT, Walsh JP, Henderson DC, Goff DC: Hepatitis C in
schizophrenia: screening experience in a community-dwelling clozapine cohort.
Psychosomatics 2007, 48(5):405–411.
66. Sockalingam S, Shammi C, Powell V, Barker L, Remington G: Determining rates of
hepatitis C in a clozapine treated cohort. Schizophr Res 2010, 124(1–3):86–90.
67. Matthews AM, Huckans MS, Blackwell AD, Hauser P: Hepatitis C testing and
infection rates in bipolar patients with and without comorbid substance use disorders.
Bipolar Disord 2008, 10(2):266–270.
68. Telio D, Sockalingam S, Stergiopoulos V: Persistent psychosis after treatment with
interferon alfa: a case report. J Clin Psychopharmocol 2006, 26(4):446–447.
20. 69. Thome J, Knopf U: Acute psychosis after injection of pegylated interferon alpha-2a.
Eur Psychiatry 2003, 18:142–143.
70. Garcia-Pares G, Domenech C, Gil M: Psychosis induced by interferon-alpha.
Psychosomatics 2002, 43:428–429.
71. Hoffman RG, Cohen MA, Alfonso CA, Weiss JJ, Jones S, Keller M, Condermarin JR,
Chiu NM, Jacobson JM: Treatment of interferon-induced psychosis in patients with
comorbid hepatitis C and HIV. Psychosomatics 2003, 44:417–420.
72. Schafer M, Boetsch T, Laakmann G: Psychosis in a methadone-substituted patient
during interferon-alpha treatment of hepatitis C. Addiction 2000, 95(7):1101–1104.
73. Constant A, Castera L, Dantzer R, Couzigou P, de Ledinghen V, Demotes-Mainard J,
Henry C: Mood alterations during interferon-alfa therapy in patients with chronic
hepatitis C: evidence for an overlap between manic/hypomanic and depressive
symptoms. J Clin Psychiatry 2005, 66(8):1050–1057.
74. Onyike CU, Bonner JO, Lyketsos CG, Treisman GJ: Mania during treatment of
chronic hepatitis C with pegylated interferon and ribavirin. Am J Psychiatry 2004,
161(3):429–435.
75. Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz
T, Middle M: A randomized evaluation of the effects of six antipsychotic agents on QTc,
in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004,
24(1):62–69.
76. Merck Canada Inc. MC: Saphris (asenapine) Product Monograph. Kirkland, QC: Merck
Canada Inc; 2013.
77. Eiermann B, Engel G, Johansson I, Zanger UM, Bertilsson L: The involvement of
CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997,
44(5):439–446.
78. Spina E, de Leon J: Metabolic drug interactions with newer antipsychotics: a
comparative review. Basic Clin Pharmacol Toxicol 2007, 100(1):4–22.
79. English BA, Dortch M, Ereshefsky L, Jhee S: Clinically Significant Psychotropic Drug-
Drug Interactions in the Primary Care Setting. Curr Psychiatry Rep 2012, 14(4):376–390.
80. AstraZeneca Canada Inc: Seroquel (quetiapine) Product Monograph. Mississauga, ON:
AstraZeneca Canada Inc; 2013. April 16.
81. Rajkumar AP, Poonkuzhali B, Kuruvilla A, Jacob M, Jacob KS: Clinical predictors of
serum clozapine levels in patients with treatment-resistant schizophrenia. Int Clin
Psychopharmacol 2013, 28(1):50–56.
82. Liukkonen T, Sorjonen M, Jokelainen J, Timonen M: Treatment of hepatitis C with
interferon-alpha and ribavirine in a patient with long-term clozapine treatment.
Psychosomatics 2008, 49(1):86–88.
21. 83. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity
for atypical and conventional antipsychotics. Life Sci 2002, 71(2):163–169.
84. Sylvestre DL, Clements BJ: Adherence to hepatitis C treatment in recovering heroin
users maintained on methadone. Eur J Gastroenterol Hepatol 2007, 19(9):741–747.
85. Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, Gallagher L, Storms
M, Raffa JD, DeVlaming S, et al: Optimizing assessment and treatment for hepatitis C
virus infection in illicit drug users: a novel model incorporating multidisciplinary care
and peer support. Eur J Gastroenterol Hepatol 2010, 22(3):270–277.
86. Luo X, Trevejo J, van Heeswijk RP, Smith F, Garg V: Effect of telaprevir on the
pharmacokinetics of buprenorphine in volunteers on stable buprenorphine/naloxone
maintenance therapy. Antimicrob Agents Chemother 2012, 56(7):3641–3647.
87. Sockalingam S, Blank D, Al Jarad A, Alosaimi F, Hirschfield G, Abbey SE: A
comparison of depression screening instruments in hepatitis C and the impact of
depression on somatic symptoms. Psychosomatics 2011, 52(5):433–440.
88. Hulskotte EGJ, Hwa-Ping F, Bruce RD, Webster LR, Xuan F, O'Mara E, Wagner JA,
Butterton JR: Pharmacokinetic interaction between HCV protease inhibitor boceprevir and
methadone or buprenorphine in subjects on stable maintenance therapy [abstract PK_09].
Cambridge, MA: 7th International Workshop on Clinical Pharmacology of Hepatitis
Therapy; 2012. Rev Antiviral Ther Infect Dis 2012;6:12.
89. Dbouk B, Arguedas MR, Sheikh A: Assessment of the PHQ-9 as a screening tool for
depression in patients with chronic hepatitis C. Dig Dis Sci 2008, 53:1100–1106.
90. Knott A, Dieperink E, Willenbring ML, Heit S, Durfee JM, Wingert M, Johnson JR,
Thuras P, Ho SB: Integrated psychiatric/medical care in a chronic hepatitis C clinic:
effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006,
101(10):2254–2262.
91. Huckans M, Mitchell A, Ruimy S, Loftis J, Hauser P: Antiviral therapy completion and
response rates among hepatitis C patients with and without schizophrenia. Schizophr
Bull 2010, 36(1):165–172.
92. Sockalingam S, Blank D, Banga CA, Mason K, Dodd Z, Powis J: A novel program for
treating patients with trimorbidity: hepatitis C, severe mental illness, and active
substance use. Eur J Gastroenterol Hepatol 2013. in press.